As value investors, we believe that the average market participant overreacts to short-term news – often related to earnings – which often has little or no impact on the long-run intrinsic value of the underlying business. We have also historically found underpriced securities in sectors deemed “uninvestable”. Many investors are still scared of banks thanks to the 2008 crisis, or avoid airlines because of the industry’s poor long-term record. If large parts of the market are unwilling to look at a particular industry regardless of valuation, then we are more likely to find mispriced securities.
Bargain British stocks to invest in
The tide went out for Standard Chartered (LSE: STAN) in 2014-2015 following the global commodities bust. The price/book value fell from three to 0.5. This led to a new (ex-JPMorgan) CEO, Bill Winters, and a long process of ridding the bank of bad loans, changing the underwriting culture and streamlining the sectors and countries the group operated in.
Today the company generates two-thirds of its profits from corporate, commercial and institutional banking and one-third from consumer, private and business banking. Over 80% of profits are generated in Asia, and the remainder in Africa and the Middle East. The bank is now sensibly run and the results have followed.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Return on equity last year was 10% and management’s goal is to reach 12% by 2026. The tier-1 capital ratio is now nearly 14%. The board is targeting net interest and other income growth of 5%-7% per annum, which they beat handily last year but would consider a healthy rate of longer-term growth. Despite all this progress, the stock trades at less than 0.7 times tangible book value.
International Airlines Group (LSE: IAG), the owner of British Airways, is one of the largest airline groups in the world and one of the “big three” European aviation operators. It operates in the passenger airlines, cargo and loyalty businesses; and it has a particularly strong foothold in the profitable transatlantic market. With its partner, American Airlines, IAG commands a 58% market share of traffic between Heathrow and the US.
Given the quality of the management team alongside the reinforced balance sheet, we view the company’s valuation as highly attractive. IAG has delivered impressive and growing profitability over the past decade, except in the Covid years. The shares trade on six times earnings and a free cash flow yield of over 10%. IAG has previously shown a willingness to return capital to shareholders, paying out 40% of today’s market value in dividends and buybacks in the five years to 2020. The company has just reinstated its dividend.
M&S is back in fashion
Marks & Spencer’s (LSE: MKS) fortunes have waxed and waned in the last two decades. They finally changed for the better in 2017 when Archie Norman was appointed chair. He had already turned around Asda. At M&S he replaced 50% of the senior management; remade the store portfolio, with brighter stores in better locations; and updated the clothing lines for modern and younger customers.
In food, the board kept the premium positioning but broadened the offering to suit a weekly shop. After years of neglect of the online arm, the board crafted a digital strategy that has made M&S one of the top online retailers in the UK. They took out about £300 million in annual operating costs at the same time.
These efforts started to bear fruit in 2023, when the group started taking market share in food, and clothing and profits exceeded forecasts. The stock has bounced from £1 to over £4 in two years but we think it is still undervalued relative to its long-run earnings potential.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription
-
Watch out for fake Steven Bartlett video – you could lose thousandsScammers are trying to tap into the Trump tariffs chaos, but knowing what to look out for could save you thousands of pounds, says Kalpana Fitzpatrick
-
Can Donald Trump fire Jay Powell – and what do his threats mean for investors?Donald Trump has been vocal in his criticism of Jerome "Jay" Powell, chairman of the Federal Reserve. What do his threats to fire him mean for markets and investors?
-
LendInvest: a promising fintech firm going cheapOpinion LendInvest has made some mistakes in the past, but it’s now primed for growth, says Rupert Hargreaves
-
The star small and mid-cap stocks income investors have overlookedOpinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
-
Falling revenues and mounting debt spell trouble for Jumia TechnologiesStruggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
-
Bargain Britain boasts both value and momentumInterview Ian Lance, manager of the Temple Bar Investment Trust, tells Andrew Van Sickle that the outlook for UK stocks has improved and healthy long-term returns are in prospect
-
Chemring Group: an explosive investment opportunity in defenceEuropean states are raising their military spending, and Chemring Group looks well placed to profit
-
Best of British bargains: cash in on undervalued companies in the UK stock marketOpinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
-
PZ Cussons share price down 75% in last decade – why it's one to watchOpinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharmaOpinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
